Search

Your search keyword '"Butler, DK"' showing total 3 results
Start Over Author "Butler, DK" Topic bnt162 vaccine
3 results on '"Butler, DK"'

1. Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure.

Author

Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC, Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter A, Pade C, Palma S, Parker R, Patel K, Pawarova M, Petersen SE, Piniera B, Pieper FP, Rannigan L, Rapala A, Reynolds CJ, Richards A, Robathan M, Rosenheim J, Rowe C, Royds M, Sackville West J, Sambile G, Schmidt NM, Selman H, Semper A, Seraphim A, Simion M, Smit A, Sugimoto M, Swadling L, Taylor S, Temperton N, Thomas S, Thornton GD, Treibel TA, Tucker A, Varghese A, Veerapen J, Vijayakumar M, Warner T, Welch S, White H, Wodehouse T, Wynne L, Zahedi D, Chain B, and Moon JC

Subjects
Animals, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Cross Reactions, Humans, Mice, Spike Glycoprotein, Coronavirus genetics, Spike Glycoprotein, Coronavirus immunology, B-Lymphocytes immunology, BNT162 Vaccine immunology, BNT162 Vaccine therapeutic use, COVID-19 immunology, COVID-19 prevention & control, Immunization, Secondary, SARS-CoV-2 genetics, SARS-CoV-2 immunology, T-Lymphocytes immunology
Abstract

The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.

Published
2022
Full Text
View/download PDF

2. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.

Author

Reynolds CJ, Gibbons JM, Pade C, Lin KM, Sandoval DM, Pieper F, Butler DK, Liu S, Otter AD, Joy G, Menacho K, Fontana M, Smit A, Kele B, Cutino-Moguel T, Maini MK, Noursadeghi M, Brooks T, Semper A, Manisty C, Treibel TA, Moon JC, McKnight Á, Altmann DM, and Boyton RJ

Subjects
Adult, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Antigens, Viral immunology, BNT162 Vaccine administration & dosage, COVID-19 Vaccines immunology, Coronavirus Nucleocapsid Proteins immunology, Cross Protection, Female, Health Personnel, Humans, Longitudinal Studies, Male, Memory B Cells immunology, Mutation, Phosphoproteins immunology, Protein Domains, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus chemistry, Spike Glycoprotein, Coronavirus immunology, T-Lymphocytes immunology, Vaccination, Vaccine Potency, BNT162 Vaccine immunology, COVID-19 immunology, COVID-19 virology, SARS-CoV-2 immunology
Abstract

The impact of the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOCs) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection plus two vaccine doses), S1 antibody, memory B cells, and heterologous neutralization of B.1.351, P.1, and B.1.617.2 plateaued, whereas B.1.1.7 neutralization and spike T cell responses increased. Serology using the Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over the 5 months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.

Published
2022
Full Text
View/download PDF

3. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants

Author

Reynolds, CJ, Gibbons, JM, Pade, C, Lin, K-M, Sandoval, DM, Pieper, F, Butler, DK, Liu, S, Otter, AD, Joy, G, Menacho, K, Fontana, M, Smit, A, Kele, B, Cutino-Moguel, T, Maini, MK, Noursadeghi, M, COVIDsortium Immune Correlates Network‡, Brooks, T, Semper, A, Manisty, C, Treibel, TA, Moon, JC, McKnight, Á, Altmann, DM, Boyton, RJ, Medical Research Council (MRC), UKRI, and Temperton, Nigel J.

Subjects
Adult, Male, COVID-19 Vaccines, COVIDsortium Immune Correlates Network‡, General Science & Technology, Cross Protection, Health Personnel, T-Lymphocytes, Antibodies, Viral, Memory B Cells, Protein Domains, Coronavirus Nucleocapsid Proteins, Humans, Longitudinal Studies, Antigens, Viral, Vaccine Potency, BNT162 Vaccine, QR355, Multidisciplinary, SARS-CoV-2, Vaccination, COVID-19, Phosphoproteins, Antibodies, Neutralizing, Mutation, Spike Glycoprotein, Coronavirus, Female, COVIDsortium Investigators‡
Abstract

Immune imprinting For severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), immune responses to heterologous variants are influenced by a person’s infection history. Healthcare workers (HCWs) may be exposed to several doses and types of antigens, either by natural infection or by vaccination. Reynolds et al . studied a cohort of UK HCWs followed since March 2020. The immunological profiles of these people depended on how often the subject had encountered antigen and which variant was involved. Vaccine responses after infection were found to be less effective if the infection involved heterologous spike from a variant virus. Unfortunately, the N501Y spike mutation, found in many variants, seems to induce the regulatory T cell transcription factor FOXP3, indicating that the virus could subvert effective T cell function. Changes to antibody binding between variants also means that serology data using the Wuhan Hu-1 S1 receptor-binding domain sequence may not be a reliable measure of protection. —CA

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results